Statements (34)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:legal_case
|
| gptkbp:applies_to |
gptkb:government_agency
|
| gptkbp:case_types |
new regulations
future pharmaceutical practices legal frameworks for drug companies |
| gptkbp:covered_by |
media extensively
|
| gptkbp:draws |
public attention
|
| gptkbp:examines |
ethical marketing
|
| gptkbp:has_impact_on |
pharmaceutical regulations
future drug marketing practices |
| gptkbp:historical_debate |
false advertising
deceptive marketing practices |
| https://www.w3.org/2000/01/rdf-schema#label |
State v. Purdue Pharma
|
| gptkbp:involves |
gptkb:Purdue_Pharma
opioid crisis |
| gptkbp:is_expected_to |
future litigation
|
| gptkbp:is_involved_in |
regulatory oversight
corporate responsibility |
| gptkbp:is_monitored_by |
legal analysts
|
| gptkbp:is_part_of |
multistate litigation
drug addiction |
| gptkbp:is_reflected_in |
societal impacts of drug abuse
|
| gptkbp:is_related_to |
addiction treatment
|
| gptkbp:is_sought_after_by |
damages
|
| gptkbp:landmark |
pharmaceutical accountability
|
| gptkbp:operational_status |
gptkb:2023
|
| gptkbp:part_of |
hold companies accountable
|
| gptkbp:participated_in |
multiple states
|
| gptkbp:resulted_in |
increased scrutiny of drug companies
|
| gptkbp:significance |
gptkb:healthcare_organization
|
| gptkbp:significant_event |
drug policy reform
|
| gptkbp:use_case |
transparency in drug marketing.
|
| gptkbp:bfsParent |
gptkb:Minnesota_State_Attorney_General
|
| gptkbp:bfsLayer |
5
|